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Design and synthesis of anticancer 
1-hydroxynaphthalene-2-
carboxanilides with a p53 
independent mechanism of action
Ewelina spaczyńska1, Anna Mrozek-Wilczkiewicz2, Katarzyna Malarz  2, Jiri Kos3, 
Tomas Gonec4, Michal oravec5, Robert Gawecki2, Andrzej Bak1, Jana Dohanosova6, 
Iva Kapustikova3, tibor Liptaj6, Josef Jampilek  7,8 & Robert Musiol  1
A series of 116 small-molecule 1-hydroxynaphthalene-2-carboxanilides was designed based on the 
fragment-based approach and was synthesized according to the microwave-assisted protocol. The 
biological activity of all of the compounds was tested on human colon carcinoma cell lines including 
a deleted TP53 tumor suppressor gene. The mechanism of activity was studied according to the p53 
status in the cell. Several compounds revealed a good to excellent activity that was similar to or better 
than the standard anticancer drugs. Some of these appeared to be more active against the p53 null cells 
than their wild-type counterparts. Intercalating the properties of these compounds could be responsible 
for their mechanism of action.
Small-molecule drugs are still most commonly used in the treatment of cancer. However, the cytostatic agents 
and DNA poisons that were initially developed for clinical use are losing their position today. The particularly 
offensive, and often even life-threatening and difficult to restrain side effects, significantly degrade the quality of 
life of patients and are often responsible for the cessation of therapy. This is the result of a non-specific mechanism 
of action and the low selectivity of these drugs. In fact, some alkylating agents are more toxic on normal cells 
than on malignant cells. Another problem that is often encountered is the resistance that may emerge after a brief 
period of a positive reaction to the therapy or may even occur in drug-naïve patients1. This phenomenon is also an 
obstacle in so-called targeted therapies that use novel agents such as kinase inhibitors as well as in non-small ther-
apeutics such as monoclonal antibodies2. Therefore, although novel small-molecule agents are still in demand, 
newly designed compounds are required to have a specific even multitargeted mechanism of action and a good 
selectivity over normal cells.
Because of their resemblance to biological structures and their great synthetic availability, simple aromatic 
amides are interesting scaffolds for designing new drugs. However, the majority of the literature data deals with 
their antimicrobial or anti-infectious activity and relatively few reports focus on their antiproliferative and anti-
cancer potency (Fig. 1)3,4. Even though salicylanilide has been claimed as privileged structure5, these compounds 
are only being developed as antibacterial4,6–8, antimycobacterial9–14, antifungal15,16 and antiprotozoic/antihel-
mintic16,17 agents or as photosynthesis inhibitors18–20. Recently, some appealing reports on simple antihelmintic 
drugs that have been used for quite some time have been published. For example, mebendazole was found to be 
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effective in selectively inducing apoptosis in cancer cells both in vitro and in vivo21. Later, the antiproliferative 
activity of mebendazole and its analog albendazole was connected with the inhibition of the hedgehog signaling 
pathway22. In addition, niclosamide, which has been used for decades as an antiparasitic drug, was rediscovered 
as an effective m-TOR inhibitor in a large library screening in 200923,24.
This resulted in a more thorough investigation that revealed its wide spectrum of activity against various cancer 
types. However, niclosamide’s multitargeted mechanism of action, which includes the inhibition of Wnt/β-catenin, 
STAT3, NF-κB, among others, is even more appealing25. It was effective in hampering cell migration and metastasis, 
thereby reducing the invasive potential of cancer cells26,27. This complex mechanism of action corresponds with 
its ability to overcome resistance in cancer cells28,29. Liu et al. recently reported that niclosamide is also capable of 
inhibiting the isoforms of the spliced androgen receptor (AR) and in overcoming drug-resistance in prostate can-
cers30. Enzalutamide is an androgen receptor antagonist that is used in the treatment of prostate cancer. However, 
in the most severe castration-resistant metastatic cancers, spliced variants of AR have been recognized. These 
forms are crucial in developing a resistance to antiandrogens including enzalutamide and flutamide31. A series of 
niclosamide derivatives with a strong anticancer potency have been identified in recent literature, e.g. the GW9662 
and T0070907, which are potent inhibitors of PPAR-γ32,33. Moreover, in addition to its antiandrogen activity, flut-
amide may have some anticancer effects via another mechanism, as was recently reported for hepatocellular carci-
noma34. These facts inspired us to perform a more in-depth investigation of the antiproliferative activity of a series of 
salicylanilides that had been designed based on those active structures. We decided to exploit the naphthalene skel-
eton to increase its lipophilicity and affinity to DNA and the replicative enzymes35. The naphthalene-bearing struc-
tures also peaked our interest to investigate their antitumor activities. In fact, the non-steroidal anti-inflammatory 
drug naproxen has also been found to have an antiproliferative effect against various cancer cells36,37. It has also been 
exploited as a leading structure in the search for new anticancer agents. Moreover, as was reported by Husain et al., 
even such a small and simple molecule may intercalate to DNA and cause photo-induced damage by reactive oxygen 
species38. Recently, some ring-substituted hydroxynaphthanilides have been synthesized and their anticancer activity 
has been reported39. In our continuing search for potential drug candidates, the present study describes the synthesis 
and antiproliferative evaluation of N-substituted 1-hydroxynaphthalene-2-carboxanilides. In this paper, we further 
report on the naphthalene compounds that exhibited strong antitumor activities against the human cancer cell lines.
Results
Naphthanilides are conjugates of naphthanilic acid and aromatic amines, which also results in their synthetic 
availability. On the other hand, no specific target has yet been proposed for similar compounds and their mecha-
nism of action appears to be multitargeted as was described for niclosamide or its analogs. With this in mind, we 
used the method of the decremental isolation of the synthons from known anticancer agents such as niclosamide 
and flutamide and similar small-molecule drugs/agents that are available by database mining5,40–43. An overview 
of this approach is presented in Fig. 2.
The substitution pattern in the amine moiety that was selected in this approach can easily be covered by a 
commercial library of building blocks. This method seems to be particularly suitable for designing easily obtain-
able compounds that have a common structural motif as we reported for anticancer thiosemicarbazones44,45 or 
antiretroviral amides46. 1-Hydroxy-2-naphthoic acid was selected for the final scaffold as was mentioned ear-
lier. The discriminative fragments that were harvested from the database search were used as the substituents 
in an aniline moiety. Due to the lack of leading structures or target specific properties, there were no clues as 
to a substitution pattern. For this reason, we decided to obtain all of the isomeric structures that were available 
(i.e. ortho, meta and para for each substituent), which permitted a deeper and more precise investigation of the 
structure-activity relationships.
Figure 1. Small molecule anilides revisited as anticancer agents.
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Chemistry. There are many methods that can be used to prepare carboxanilides. The compounds that were 
used were synthesized using a one-pot microwave-assisted synthesis47. Microwave-assisted organic chemistry is well 
known for its high efficiency and good yield and purity and can be used in synthesis of a wide assortment of com-
pounds including nanomaterials48,49, multicomponent reactions50,51 and heterocyclic compounds52,53 among others. 
This approach can be also used for homo-and hetero-catalyzed reactions54,55. It is also very useful in the synthesis 
of fragile compounds that decompose easily, for example, in the synthesis ofcarbohydrates56 or for the introduction 
of nitro groups57. In the synthesis of larger libraries of compounds such an approach has significant advantages58,59.
The condensation of 1-hydroxy-2-naphthoic acid with ring-substituted anilines using phosphorus trichloride in 
chlorobenzene under microwave conditions yielded a series of N-substituted 1-hydroxynaphthalene-2-carboxanilides 
1–8d. The carboxyl group was activated with phosphorus trichloride first. The final amide was immediately formed 
via the aminolysis of acyl chloride by ring-substituted aniline in dry chlorobenzene. The tentative mechanism of this 
synthesis seems to be identical to conventional conditions without any special microwave effects. The compounds 
that were studied were prepared according to Fig. 3. All of the compounds were recrystallized from ethyl acetate or a 
mixture of solvent ethanol/water. Their HPLC purity exceeded 98%, and the yields were more than 70% in most cases.
Biological activity tests. Antiproliferative assay. All of the synthesized compounds were tested for their anti-
proliferative activity against human colon cancer (Table 1). We used both the wild-type and p53-negative cell lines 
(HCT116+/+ and HCT116−/−, respectively). Mutations in the TP53 gene are present in more than 50% of all cancers 
and often specifically correspond to a difficult therapy, resistance or a bad prognosis60–63. The active compounds were 
additionally tested for their cytotoxicity against normal human fibroblasts. We used 5-fluorouracil (5-FLU), doxoru-
bicin (DOX) and CP-31398 as the standards. 5-FLU is one of the first antimetabolites that was dedicated for cancer 
treatment and is still used for a wide range of cancers including colon carcinoma64. Doxorubicin is a DNA topoisomer-
ase II poison with a high intercalating potency, which is able to induce apoptosis through the p53 pathway65. Although 
DOX has been described as being ineffective in some p53 mutants, its level of activity against the p53 null lines is simi-
lar66. CP-31398, on the other hand, is an experimental drug in the clinical phase and its mechanism of action is through 
the reactivation some of p53 mutants. Its activity against the p53 null cell lines is greatly diminished and is actually lower 
than its cytotoxicity67.
Figure 2. Design of the target amides. Compounds with an anticancer activity provided amine-derived 
fragments, which were further divided into substituents. The final structure was a combination of all of the 
fragments.
Figure 3. Synthesis of ring-substituted 1-hydroxynaphthalene-2-carboxanilides 1–8d. Microwave irradiation 
(MW) conditions: 120–130 °C; 500 W; 50 minutes R = H, OCH3, F, Cl, Br, CF3, NO2.
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No.
Activity IC50 [μM]
HCT116+/+ HCT116−/− NHDF
1 H* >25 >25 —
2a 2-OCH3* >25 >25 —
2b 3-OCH3* 8.51 ± 1.69 24.05 ± 3.54 >25
2c 4-OCH3* >25 >25 —
2d 2,5-OCH3 >25 >25 —
2e 3,5-OCH3 >25 >25 >25
2f 3,4,5-OCH3 6.54 ± 2.42 8.78 ± 2.13 >25
2g 2-OCH3-4-NO2 2.62 ± 0.85 3.73 ± 1.09 7.53 ± 2.97
2h 2-OCH3-5-NO2 7.05 ± 1.75 7.42 ± 2.05 >25
2i 2-OCH3-5-CF3 >25 >25 —
2j 2-OCH3-5-CH3 >25 >25 —
2k 2-OCH3-6-CH3 >25 >25 —
3a 2-CH3* >25 >25 —
3b 3-CH3* >25 >25 —
3c 4-CH3* >25 >25 —
3d 2,5-CH3 >25 >25 —
3e 2,6-CH3 >25 >25 —
3f 3,5-CH3 19.31 ± 1.68 >25 >25
3g 2,4,6-CH3 >25 >25 —
3h 2-CH3-5-OCH3 11.65 ± 3.81 >25 >25
3i 2-CH3-5-CF3 8.41 ± 1.07 5.08 ± 1.23 >25
4a 2-F* >25 >25 —
4b 3-F* 1.88 ± 0.33 9.02 ± 1.91 >25
4c 4-F* 2.49 ± 0.61 5.01 ± 1.12 >25
4d 2,4-F 6.55 ± 0.83 11.41 ± 1.92 >25
4e 2,5-F 4.76 ± 0.76 15.05 ± 6.75 >25
4f 2,6-F >25 >25 —
4g 3,4-F 3.04 ± 0.06 5.88 ± 0.50 22.21 ±  ± 1.61
4h 3,5-F 1.79 ± 0.44 2.24 ± 0.30 9.87 ± 0.66
4i 2,3,4-F 4.28 ± 0.66 4.43 ± 0.66 >25
4j 2,4,5-F 1.87 ± 0.35 4.75 ± 0.05 24.52 ± 0.03
4k 2,4,6-F >25 >25 —
4l 3,4,5-F 1.19 ± 0.31 1.42 ± 0.25 10.04 ± 0.54
4m 2,3,5,6-F 11.95 ± 0.92 >25 >25
4n 2,3,4,5,6-F 11.59 ± 0.74 17.54 ± 0.76 >25
4o 2-F-3-Cl 8.78 ± 2.18 6.76 ± 2.37 >25
4p 2-F-3-CF3 6.50 ± 1.16 5.45 ± 1.72 24.44 ± 2.51
4q 2-F-4-Cl 9.89 ± 3.26 9.69 ± 3.13 >25
4r 2-F-4-Br 14.99 ± 4.82 3.43 ± 0.69 >25
4s 2-F-5-Cl 8.66 ± 1.61 10.66 ± 1.73 >25
4t 2-F-5-Br 11.94 ± 1.28 14.01 ± 2.2 >25
4u 2-F-5-CF3 10.05 ± 2.61 7.45 ± 1.74 >25
4v 3-F-4-Br 10.86 ± 2.69 12.43 ± 1.11 >25
4w 3-F-4-CF3 3.25 ± 0.94 4.82 ± 1.46 22.82 ± 2.69
4× 3-F-5-CF3 9.01 ± 0.45 >25 24.12 ± 2.02
4y 2,3,5,6-F-4-Br 2.41 ± 0.69 5.68 ± 1.37 7.87 ± 1.37
4z 2,5-F-4-CF3 4.22 ± 0.87 2.82 ± 0.77 18.35 ± 0.91
5a 2-Cl* 16.49 ± 2.25 22.44 ± 3.58 >25
5b 3-Cl* 4.70 ± 0.40 1.78 ± 0.32 >25
5c 4-Cl* 9.62 ± 0.75 9.41 ± 0.78 >25
5d 2,3-Cl‡ 4.66 ± 0.58 8.25 ± 0.64 >25
5e 2,4-Cl‡ 1.95 ± 0.50 6.06 ± 1.13 >25
5f 2,5-Cl‡ 7.45 ± 0.85 7.19 ± 1.15 >25
Continued
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No.
Activity IC50 [μM]
HCT116+/+ HCT116−/− NHDF
5g 2,6-Cl‡ >25 >25 —
5h 3,4-Cl‡ 5.15 ± 0.50 4.74 ± 0.82 >25
5i 3,5-Cl‡ 2.32 ± 0.26 2.89 ± 0.38 11.47 ± 0.88
5j 2,4,5-Cl‡ 3.00 ± 0.24 6.21 ± 0.66 20.19 ± 0.79
5k 2,4,6-Cl‡ 19.37 ± 1.27 >25 >25
5l 3,4,5-Cl‡ 1.31 ± 0.15 2.86 ± 0.33 7.01 ± 0.42
5m 2-Cl-4-F 7.57 ± 2.16 8.29 ± 2.92 >25
5n 2-Cl-4-Br‡ 2.33 ± 0.95 9.79 ± 1.95 23.45 ± 0.86
5o 2-Cl-4-CF3 4.92 ± 1.32 5.41 ± 1.11 13.18 ± 1.97
5p 2-Cl-5-OCH3 24.10 ± 2.58 19.31 ± 2.09 >25
5q 2-Cl-5-Br‡ 4.18 ± 1.49 5.40 ± 2.04 >25
5r 2-Cl-5-CF3 2.48 ± 0.31 1.46 ± 0.21 12.40 ± 1.14
5s 3-Cl-4-F 6.87 ± 2.48 0.83 ± 0.31 >25
5t 3-Cl-4-Br‡ 12.35 ± 0.79 12.58 ± 0.69 >25
5u 2-Cl-3,5-CF3 0.72 ± 0.28 2.72 ± 0.63 16.30 ± 1.28
5v 2,6-Cl-4-CF3 >25 >25 —
6a 2-Br* 22.51 ± 3.62 >25 >25
6b 3-Br* 9.19 ± 0.98 8.73 ± 0.89 15.21 ± 2.48
6c 4-Br* 5.25 ± 0.67 11.01 ± 0.97 >25
6d 2,4-Br‡ 4.56 ± 0.43 4.61 ± 0.72 >25
6e 2,5-Br‡ 5.24 ± 0.28 5.85 ± 0.61 >25
6f 2,6-Br‡ >25 >25 —
6g 2,4,6-Br‡ >25 >25 —
6h 2-Br-4-Cl‡ 9.54 ± 2.71 13.23 ± 2.3 >25
6i 2-Br-4-CF3 3.58 ± 1.25 2.19 ± 0.67 18.42 ± 1.23
6j 2-Br-5-F 7.78 ± 1.37 5.83 ± 1.06 >25
6k 2-Br-5-CF3 8.18 ± 1.72 7.15 ± 1.96 22.23 ± 0.83
6l 2,6-Br-4-CF3 9.37 ± 0.47 6.81 ± 2.66 20.37 ± 1.16
6m 2,6-Br-3-Cl-4-F >25 >25 —
7a 2-CF3* >25 21.36 ± 1.24 —
7b 3-CF3* 6.25 ± 0.47 1.39 ± 0.29 >25
7c 4-CF3* 4.31 ± 0.51 1.07 ± 0.26 16.57 ± 2.17
7d 2,4-CF3 11.31 ± 1.31 8.69 ± 1.02 >25
7e 2,5-CF3 4.44 ± 1.16 8.53 ± 3.37 22.93 ± 2.10
7f 3,5-CF3 0.46 ± 0.05 0.35 ± 0.08 3.55 ± 0.76
7g 2-CF3-4-F >25 >25 —
7h 2-CF3-4-Cl >25 >25 —
7i 2-CF3-4-Br >25 >25 —
7j 2-CF3-4-NO2 2.04 ± 0.71 4.74 ± 1.68 12.55 ± 1.32
7k 3-CF3-4-OCH3 >25 >25 —
7l 3-CF3-4-CH3 >25 >25 —
7m 3-CF3-4-F 11.96 ± 3.68 14.49 ± 4.53 >25
7n 3-CF3-4-Cl 9.66 ± 3.17 18.72 ± 2.78 >25
7o 3-CF3-4-Br >25 13.90 ± 3.75 >25
7p 3-CF3-4-NO2 1.64 ± 0.47 1.39 ± 0.44 9.68 ± 1.49
8a 2-NO2* 23.32 ± 3.77 >25 22.71 ± 2.71
8b 3-NO2* 6.82 ± 1.17 3.10 ± 0.63 >25
8c 4-NO2* 0.41 ± 0.05 0.69 ± 0.09 12.30 ± 1.49
8d 2-NO2-4-CF3 >25 >25 —
— 5-FLU 4.42 ± 0.70 4.69 ± 0.31 >25
— DOX 0.34 ± 0.04 0.38 ± 0.03 3.38 ± 1.29
— CP-31398 18.63 ± 0.92 26.28 ± 1.41 12.26 ± 0.54
Table 1. The antiproliferative activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides. 
*Compounds described in88, ‡compounds described in18.
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Modeling the drug activity using the CoMFA/CoMSA and SMV procedure. The main objective of 
the ligand-based modeling was to perform a systematic study of the performance of CoMFA/CoMSA in mode-
ling the in vitro activity that was observed for the set of 1-hydroxynaphthalene-2-carboxanilides derivatives, 
which showed a high antiproliferative activity against human colon cancer. Hence, the pharmacophore properties 
of a target series using a coupled neural network and the PLS method with the variable elimination IVE proce-
dure were scrutinized. We compared the findings of the activity modeling using the standard 3D methodology 
(CoMFA) and its neural counterparts (CoMSA) regarding multiple training/test subsets and the (in)dependent 
variables being used. Unfortunately, the qcv
2  performance of the toxic profile for the entire 
hydroxynaphthanilide-based dataset 1–8d in the training dataset was not satisfactory for the CoMFA (qcv
2  ≈ 0.5, 
SDEP ≈ 0.30) and CoMSA models (qcv
2  ≈ 0.5, SDEP ≈ 0.25), regardless of the probe atom type (CH3+, H+, CH30) 
or the map size (10 × 10 ÷ 30 × 30) and the template molecules that were applied (1, 2f, 4l, 4n, 7f, 8c). However, 
the quality of the HCT116+/+ models that were generated in terms of qcv
2  was slightly better compared to 
HCT116−/− and NHDF. It seems that the following rank of qcv
2 (HCT116+/+) > qcv
2 (HCT116−/−) > qcv
2 (NHDF) val-
ues is partially determined by the number of constants or missing activity data, e.g. ≈ 30% of HCT116+/+, ≈ 35% 
of HCT116−/− and ≈72% of NHDF, respectively. It is worth mentioning, that the molecular lipophilicity that was 
evaluated by the calculated logP value (clogP) as an extension of the descriptor pools had only a minor effect on 
the modeling outcomes. It is obvious that the predictive power of a model cannot be evaluated only by the good-
ness of fit of the data with the cross-validated leave-one-out procedure (CV-LOO); therefore, the exclusive reli-
ance on a training set is insufficient to specify the robustness of models68. Consequently, an external validation in 
which the molecule subset was divided into a training/test collections was applied to evaluate the predictive 
ability of the model with SDEP and qtest
2  statistics. The CoMFA/CoMSA performance for the models, which were 
arbitrarily divided into the training/test subsets at a 2:1 ratio (68/34) and ranked according to the antiproliferative 
activity (in HCT116) was also examined. Additionally, the Kennard-Stone algorithm was used on the dependent 
variables to divide the data collection into training/test subgroups representatively68. In all of the cases, the best 
CoMFA/CoMSA qcv
2 /qtest
2  outcomes performed comparably and indicated pretty poor model abilities, which were 
accompanied by a poor predictive power of the model. The obtained findings confirmed that a priori dividing 
objects into training/test subgroups with a restricted ensemble of molecules that is assigned with activity data is 
not a trivial issue; therefore, an additional assessment, namely the Stochastic Model Validation (SMV), was con-
ducted as a ‘perturbation’ procedure to examine the data structure69.
Consequently, the repetitive sampling of the original compound ensemble (102 molecules) into training/test 
subseries each containing 68/34 molecules (fraction 2/3 to 1/3) was conducted iteratively in order to determine 
any variations in the statistical estimators. Due to resource and time constraints, the examination of all of the 
possible combinations C102
34  ≈ 1.31 × 1027 was not technically feasible, and therefore the overall number of sam-
plings was restricted to a relatively small fraction of 106 populations, which were systematically generated and 
subsequently used in the PLS modeling. The observed distribution of the qcv
2  vs. qtest
2  pattern confirmed the intui-
tive interpretation of the qcv
2 /qtest
2  fluctuation pattern, where a higher modeling power within the training set can 
be specified for the HCT116 potency (qcv
2  ≥0.70). Conversely, the preferential selection of the objects into the 
training sets that fit into the model, resulted in a decrease in the predictive ability for the residual objects, which 
confirmed the dual nature of the qcv
2 /qtest
2  parameters, in which a high value of qcv
2  does not imply a good model 
predictability69.
On the other hand, it should be stressed that the great advantage of the QSAR/QSPR paradigm does not lie in 
the extrapolation, and therefore we focused more on the descriptive aspects of the molecular modeling. 
Interestingly, the answers to the inspected training/test perturbations (qcv
2> 0.5 & qtest
2 >0) in the form of popula-
tion maps revealed that the HCT116+/+ models formed more densely populated clusters compared to HCT116−/−. 
Figure 4 illustrates the molecule selection frequency into the test sets as a function of the compound number 
when sampling the best models (qcv
2  ≥0.60 & qtest
2 >0). Noticeably, the relatively smooth compound distribution 
within the training/test subpopulations was disturbed by the outnumbering of 25 molecules with a count fre-
quency ≥1,000 (2c, 2h, 2i, 4a-4d, 4q, 4u, 4y, 4z, 5c, 5d, 5n, 5o, 5p, 5q, 5t, 6a, 6d, 6l, 7b, 7e, 7m, 7o). Generally 
speaking, the specified molecules were mainly ortho- and/or para-substituted isomers with electron-withdrawing 
substituents. Interestingly, the anticancer activity for the mono-positioned isomers can be ranked according to a 
rough relation in which ortho <meta/para, which partly explains the preferential selection of the meta-positioned 
molecules into a training subset. Following the SMV CoMSA findings, the indicated molecules were also elimi-
nated from the training sets in the CoMFA modeling of the activity profile (test sets: 2c, 2h, 2i, 4a-4d, 4q, 4u, 4y, 
4z, 5c, 5d, 5n, 5o, 5p, 5q, 5t, 6a, 6d, 6l, 7b, 7e, 7m, 7o). In this case, the best CoMFA/CoMSA models were com-
parable (CoMSA: qcv
2  = 0.71 vs. CoMFA qcv
2  = 0.73).
Induction of apoptosis. Three compounds with a distinct activity were selected for further tests. These were 
7 f, which was the most active with no selectivity; 5u, which was roughly four times more active against the wild 
type and 5s due to its preference for the p53 null cells. The apoptosis of the cells that were treated with the active 
compounds was confirmed using the Acridine Orange (AO)/Ethidium Bromide (EB) staining test70 (Fig. 5). For 
active compounds 5u, 5s and 7f, we observed early and late apoptotic cells in the HCT116 colonies.
The cells were stained with AO/EB to indicate apoptosis. The cells that were treated with anilides showed early 
apoptotic features – green and yellow cells (green dots in the nuclei indicate chromatin condensation and nuclear 
fragmentation) and late apoptotic cells – orange cells with condensed and fragmented nuclei.
Further exploration of the cell death model was performed by a western blot analysis of protein activation 
in response to incubation with the tested compound (Figs 6, 7). As was expected, incubation with DOX led 
to a dramatic increase in the amounts of the p21 and p53 proteins in the wild-type colon carcinoma cells. The 
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Figure 4. Number of individual compounds that appeared in the test set within >0.6 and >0 for the 
HCT116+/+ potency of the hydroxynaphthanilide derivatives using the CoMSA method.
Figure 5. The morphological changes of the HCT116 p53+/+ (A) and HCT116 p53−/− (B) cells after a 48-hour 
treatment with 5u, 5s and 7f. The cells were stained with AO/EB to indicate apoptosis. The cells that had been 
treated with anilides showed early apoptotic features – green and yellow cells (green dots in the nuclei indicate 
chromatin condensation and nuclear fragmentation) and late apoptotic cells – orange cells with condensed and 
fragmented nuclei. Scale bars = 50 μm.
Figure 6. Influence of the active anilides and DOX on the activation of the p53/p21 system in the HCT116 cells 
(A). A densitometric analysis of the expression of the p21 protein normalized to GAPDH. The results are the 
mean ± SD of three independent experiments (B). Uncropped expositions are presented in Figure S5 in the 
Supplementary Information.
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proapoptotic activation of the p53/p21 system was noticeable after the first 12 hours and then became stronger 
after 24 h. This effect was not observed in the case of the p53 null cells, which were unable to synthesize this 
protein. In contrast, the three tested anilides did not cause the activation of p53. However, a small, insignificant 
increase of p21 was observed for 5u and 5s in the p53 null cells after the first 12 hours. It was also noticeable that 
the non-selective compound 7f did not increase p21 in either of the lines that were tested.
DNA intercalation. The fused aromatic rings of the naphthalene moiety and halogen substituents in aniline 
may guarantee good intercalating properties71,72. On the other hand, the intercalation of DNA may explain the high 
activity against both the wild-type and p53 mutants as was reported for a series of styrylquinolines67. Binding to 
DNA causes the bases to mismatch or cleave, which results in the arrest of the cell cycle and apoptosis. The effec-
tiveness of the p53 system is one of the most important factors in the response to therapy73. We tested the interca-
lating properties of the selected compounds in a spectrophotometric assay on calf-thymus DNA. The absorption 
spectra of the tested compounds in the absence and presence of CT-DNA are presented in Figure S1 Supplementary 
Information and the spectral properties with doxorubicine and CP-31398 are summarized in Table 2.
Discussion
Generally, most of the compounds that were tested in this study appeared to be active and more than 50 reached 
a micromolar level of activity (IC50 <10 μM), which is comparable with the standard drugs. The most active 
compounds were 8c and 7f, which had a submicromolar activity level and IC50 0.415 and 0.464, respectively, 
for the HCT116 wild type. However, 8c also had a preferable low cytotoxicity against the normal cell line and a 
selectivity index of 30. Noticeably, the p53 status had little effect on the majority of the compounds that appeared 
to be active. In many cases, the wild-type colon carcinoma was more sensitive to those anilides. However, some 
of the agents that were tested were particularly interesting because of their intriguing selectivity towards the p53 
null cells. Among them, 5s was more than eight times more toxic against HCT116 p53−/− than its wild-type coun-
terpart. Its low cytotoxicity in normal cells (selectivity index >30) make it even more valuable. Surprisingly, other 
compounds with a substitution pattern that was similar to 5h, 5t and 4v were not selective for the p53 mutant 
with the exception of 6j and 4r. Notably, 4r, which is roughly 4.5-fold more effective against p53 null cells, shares a 
Figure 7. CoMSA IVE-PLS monitored for the 68/34 training/test set samplings. The plots show the spatial 
areas with the strongest influence to the HCT116+/+ activity. Colors coding the sign of this impact (a). Four 
possible combinations of the mean charge and correlation coefficient are color coded (b). Compound 1 as a 
reference molecule was plotted in two different orientations.
Comp
Absorption 
λmax [nm]
Changes in 
absorbance % hypochromism Δε [M−1cm−1]
red shift* 
[nm]
5s 264; 380 hypochromism 6.5 255.6 2
5u 282; 380 hypochromism 14.0 922.2 2
7f 282; 382 hypochromism 5.7 244.4 0
DOX 480 hypochromism 34.2 3235.6 10
CP-31398 312; 350 hypochromism 41.4, 37.4 1515.6; 1693.3 0
Table 2. Absorption spectral properties of the tested compounds bound to CT-DNA. *for the wavelengths of 
the maximum absorption for the individual and DNA-bound compounds.
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similar 2-fluoro substitution with 5s. Generally, mono- and di-halogen are required as substituents for anticancer 
activity. This is clearly visible compared to the methyl or methoxy substituents (compare 2c and 4c). On the other 
hand, tetra- or penta-substituted naphthanilides are less active.
Moreover, Principal Component Analysis (PCA) for the set of descriptors that were derived from the Dragon 
6.0 software was applied to the analyzed compounds. From the initial number of selected parameters (4,885), all of 
the columns with constant or nearly constant values (standard deviation <10−4) and with missing values were 
excluded at the preprocessing stage, thus resulting in a final set of 2,916 descriptors. Finally the dataset was organ-
ized in an X102 × 2916 matrix with the objects (molecules) gathered in rows and their numerical parameters in col-
umns, for further analysis. The examination of any (dis)similarities between the objects that were studied required 
the simultaneous consideration of all of the calculated parameters. Thus, PCA was used to visualize any major 
variations in the performance of the investigated molecules according to their structure and profile of anticancer 
activity. The analysis was conducted for centered and standardized data, since the studied data library included 
parameters with various orders of magnitude. The percentage of modeled variance was applied to determine the 
number of significant principal components (PCs). The PCA model with the first four PCs described 70.72% of the 
total data variance, while the first three PCs accounted for 66.15%. Not surprisingly, the efficiency of the data com-
pression when PCA was used implied a pretty strong correlation between the variables in the data set that was 
analyzed. An analysis of the score plots for PC1 vs. PC2, which are presented in Figures S2, S3 Supporting 
Information, indicated that the hydroxynaphthanilide analogs can be classified into groups according to their 
structural data – the positional isomers were generally grouped together. The mono-substituted halogen isomers 
(4–6) were located together as well as the mono-/di-/tri-substituted methyl and methoxy derivatives 2a-f, 2j, 2k, 
3a-h. Compounds with the CF3 group and the halogen atom created a separate cluster (4w, 4×, 5o, 5r, 6k, 7g, 7h, 
7i, 7m, 7n, 7o), which was similar to the di-halogenated positional isomers (4d-h, 5d-I, 5q-t, 6d-f, 6h). 
Additionally, 13 of the descriptors (see Table S1 Supplementary Information) that were produced by the Sybyl 
software were selected, including the count, volume, surface, Ro5 and lipophilicity parameters in order to investi-
gate the variations within the set of hydroxynaphthanilide derivatives. The compression of the data increased 
slowly along with the number of PCs, that were considered. The first two PCs accounted for 79.47% of the total data 
variance and this increased to ca. 93.16% for the next four PCs. The projection of the objects onto the plane, which 
was defined by the PC1 vs. PC2 component (Figures S2, S3 Supporting Information), confirmed the dissimilarity 
of compound 5u from the other molecules that were previously observed. Interestingly, a dense cluster of objects 
was observed along the first principal component (PC1 >0), in which the remaining ones were basically 
methoxy-based analogs. Compounds that are have similar structures, (chemotypes) should have similar property 
features – this is the working tenet of QSPR. The lipophilicity of the tested compounds (color-coded according to 
the values of clogP that were calculated) projected on the plane that was specified by the two components (PC1 vs. 
PC2) confirmed the tendency of the compounds to separate along PC1 as is illustrated in Figure S4 supporting 
information. Based on the loading plots, it can be concluded that the uniqueness of the above-mentioned mole-
cules was caused by the positively correlated variables that described the molecular properties. However typically 
in mD-QSAR when enormous number of topologic/topographic-based descriptors are generated this increa the 
probability of variable overfitting and co-linearity. Thus elimination of variables is not a pre-processing procedure 
used to prune the input assembly/ensemble of the descriptors but it can be successfully used to simplify the inter-
pretability of a model since fewer descriptor terms are examined. The automated IVE-PLS method was employed 
as a filter to identify the structural descriptors that had the highest individual weightings to the biological activity69. 
A simplified visual inspection of the pharmacophore pattern that was generated gave a clear 3D landscape of the 
areas that should be altered in order to improve the biological activity. Hence, all 68/34 training/test samples (spec-
ified for the regions with pretty high model abilities qcv
2  ≥0.6 & qtest
2 >0) were used to generate a combined pharma-
cophore. The columns with the highest stability for each of models that were randomly selected, were identified by 
the IVE-PLS methodology. The moment that qcv
2  deteriorates indicate the number of columns that appeared rele-
vant. Thus backward elimination of the columns war recurrently repeated until the optimal number of variables to 
be included within the model was achieved. The cumulative sum of the common columns for all of the investigated 
HCT116+/+ models was calculated and normalized to the range of [0 ÷ 1]. Originally, the group of columns with a 
value above the pre-selected cut-off of 0.8 was selected and the spatial pattern that is illustrated in Fig. 7 was gener-
ated by further filtering 80% of the CoMSA descriptors that had a relatively small statistical significance for the 
HCT116+/+ activity profile, respectively. The relative contribution of each variable was weighted by the magnitude 
and the corresponding regression coefficient, and color code was used to sign of the impact of a descriptor on the 
compound potency. The sign of the influence is color coded and not only depicts the regions with a positive or 
negative activity, but also for possible combinations of the mean charge or correlation coefficient.
The displayed arrangement of the 3D maps presented in Fig. 7 indicates the spatial areas that had a relatively 
huge impact (positive or negative) on the antiproliferative activities of the investigated molecules. The dark circles 
in Fig. 7a designate the fragments that are less favourable for the HCT116+/+ potency (due to steric hindrance or 
electrostatic factors). The bright polyhedral areas specifies the 3D patterns where an atom or substituent is fore-
seen to be positively influential for the antiproliferative activity.
Noticeably some regions in which a positive influence was indicated appeared similar to the amide bond 
which can be regarded as peptide-bond-like motif. The carbonyl moiety can contribute to the energy of the 
guest-host interaction (enthalpic factor) via the possible generation of hydrogen bond(s) with the target counter-
part. Moreover, the hydrogen in N-H, can be important for the bonding affinity as hydrogen bond donor, which 
was designated by the positive regression coefficient area denoted in Fig. 7b. This illustrate the significance of the 
substituent R, attached directly to the phenyl ring (according to Fig. 3), and position meta- and para- seem to be 
critical factors for the activity of the compounds that were. Indeed, a mixed electrostatic influence to the activity 
can be noticed for the meta and para substitution (see Fig. 7b). Regarding the spatially allowed regions with the 
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negative regression coefficient of CoMSA models, the molecules with higher electron density in the meta posi-
tion positively contributed to the activity profile proportionally to the C-X bond length, e.g. C-F < C-Cl < C-Br. 
Conversely, the positive regression coefficients in this particular region probably mean that some polar (elec-
tropositive) atom(s) might enhance the potency of the HCT116+/+ compounds as was observed for the CF3- and 
NO2-substituted compounds within the population of meta/para structures. Moreover, the bulky substituents at 
position 4′ of the phenyl ring seems to be an unfavorable and explain the lower activity of the para isomers against 
HCT116+/+ cancer cells.
Deeper insight into the antiproliferative activity of the hydroxynaphthanilides included the cell death mode 
and the determination of the key proapoptotic proteins for selected compounds. Programmed cell death – apop-
tosis – can be triggered via several different pathways. The most typical one in response to cytotoxic agents such 
as the majority of anticancer drugs is the disruption of homeostasis, which leads to the activation of the p53 
protein74. This tumor-suppressor protein is responsible for detecting cellular stress and initiating either DNA 
repair or cell suicide. In order to achieve this, p53 acts as a gene regulator and an activator of downward factors 
such as the p21 protein, thereby leading to the extrinsic and intrinsic pathways74,75. This protein is also activated 
in response to various anticancer drugs from antimetabolites to topoisomerase inhibitors and radiation76,77. The 
most common mechanism consists of cytochrome C leakage for the mitochondria, the activation of caspases and 
the formation of apoptosome74. Thus, a mutation in the TP53 gene often causes an increased drug resistance and 
a decreased treatment response. The p53/p21 system has been established to be the main trigger of apoptosis in 
colon carcinoma that is treated with doxorubicin65.
These results suggest that the tested anilides activate the p53-independent pathway of apoptosis, which can be 
supported by the observation of the proapoptotic proteins that were assayed. These are shown in Figure S5 supple-
mentary information. Specifically, we did not observe the cleavage of caspases-8 and −9 to the tested compounds. 
An exception was 5s, which caused some cleavage in the case of the p53 null cells but not in the wild-type cells. 
This observation corresponds with the high selectivity of 5s towards the p53−/− cell line. Moreover, no activation 
of caspase-8 or AIF was detected after incubation with the tested anilides. Similarly, the cytochrome c level was 
unaffected. Leakage of cytochrome c from the mitochondria is the first step of caspase-dependent apoptosis, 
which is often initiated by p53 activation78. With this in mind, these results confirm a p53-independent pathway 
as was suggested. On the other hand, cleavage of PARP as well as a small but evident increase in the PARP level in 
response to the active compounds was observed. PolyADP-ribose polymerase is the nuclear factor that is respon-
sible for detecting and repairing single strand breaks in DNA79. Its inhibition by the cleavage that is induced with 
caspase-3 is also a classic sign of apoptosis. However, the complex role of this protein is still vague especially in 
terms of any alternative activation and deactivation factors80,81. Special attention is being paid to alternative ways 
of cell death for their potential usefulness in designing selectively targeted drugs82–84.
In general, the drug-DNA interactions may induce the hypo- or hyperchromism of the testing mixture. The 
latter reflects the electrostatic binding to the grooves or the partial uncoiling of the helix. Hypochromism, on the 
other hand, is attributed with the interaction of the electronic states of the ligand and DNA bases, tight complex 
and π-stacking and is typically regarded as a sign of intercalation. Usually, this effect is connected with a red or 
blue shift of the spectra. The strength of a wavelength shift and hyperchromism reveal the interaction strength. 
Although the tested compounds can be regarded as intercalators, their binding properties are lower than strong 
ligands such as DOX. Moreover, some interesting regularities can be observed. Compound 7f revealed a rather 
low hypochromic effect and no wavelength shift, which may suggest that its activity is exerted by another mech-
anism. Two selective compounds showed signs of stronger interactions especially in the case of 5u where a 14% 
lower intensity was connected with a small red-shift of the spectra. Moreover, 5s revealed some intercalating 
properties, which may explain its activity and selectivity. Interaction with DNA results in a small amount of dam-
age that may induce the repair system, arrest the cell cycle and ensure the survival of a cell with a fully functional 
p53. In mutants, however, incubation with even a small concentration of the compound may result in accumu-
lating damage and cell death according to an alternative pathway. As was previously reported, the survival of a 
cell depends on the p53 activation from a stimulus that is triggered by DNA damage85. In p53-defective cells, 
the activation of PARP may not guarantee the successful escape from the death pathway, which is observed as a 
higher activity of the tested compounds, e.g. a lower IC5067,86,87.
To sum up, a series of aromatic 1-hydroxynaphthalene-2-carboxanilides were designed based on selecting 
decremental fragments from the literature data. One hundred sixteen compounds were synthesized according 
to the simple microwave-assisted method, which affords high yields and purity. All of the compounds were 
tested for their antiproliferative activities against the human colon cancer cell lines HCT116 wild type and with 
a deletion of the TP53 suppressor gene. The influence of the substitution pattern on the activity was revealed 
using COMSA and COMFA analyses. Several of those compounds showed a promising activity against the p53 
mutants. Interactions with DNA seem to be involved in the mechanism of action that triggered apoptosis appar-
ently on an s caspase-independent pathway. To summarize, our work shows that simple, small molecular aromatic 
amides may be valuable leading structures in the development of anticancer drugs.
Materials and Methods
Chemistry. All of the reagents were purchased from Sigma-Aldrich and Merck. Reactions were carried out in 
a StartSYNTH microwave lab station (Milestone, Sorisole BG, Italy). Thin layer chromatography was performed 
on alumina-backed silica gel 40 F254 plates (Merck, Darmstadt, Germany). The plates were illuminated under UV 
(254 nm) and evaluated in an iodine vapor. The melting points were determined on a Kofler hot-plate apparatus 
(HMK Franz Kustner Nacht BG, Dresden, Germany) and are uncorrected. The purity of the final compounds 
was checked by the HPLC separation module Waters Alliance 2695 XE (Waters Corp., Milford, MA, USA). A 
detection wavelength of 210 nm was used. The peaks in the chromatogram of the solvent (blank) were deducted 
from the peaks in the chromatogram of the sample solution. The purity of individual compounds was determined 
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from the area peaks in the chromatogram of the sample solution. Infrared (IR) spectra were recorded on a Smart 
MIRacle™ ATR ZnSe for Nicolet™ Impact 410 FT-IR spectrometer (Thermo Scientific, West Palm Beach, FL, 
USA). The spectra were obtained by the accumulation of 64 scans with a 2 cm−1 resolution in the region of 4,000-
650 cm−1. All 1H and 13C NMR spectra were recorded on a Bruker Avance III 400 MHz FT-NMR spectrometer 
(400 MHz for 1H and 101 MHz for 13C (Bruker Comp., Karlsruhe, Germany) or an Agilent VNMRS 600 MHz 
system (600 MHz for 1H, 151 MHz for 13C and 565 MHz for 19F (Agilent Technologies, Santa Clara, CA, USA) in 
DMSO-d6. Chemical shifts are reported in ppm (δ) using the signal of the solvent (DMSO-d6) as the reference 
(2.500, resp. 39.50) against the internal standard, Si(CH3)4. Trifluoroacetic acid was used as the standard for 19F 
NMR (δ = −76.55). High-resolution mass spectra were measured using a Dionex UltiMate® 3000 high-perfor-
mance liquid chromatograph (Thermo-Fisher Scientific, Waltham, MA, USA) coupled with a LTQ Orbitrap XLTM 
Hybrid Ion Trap-Orbitrap Fourier Transform Mass Spectrometer (Thermo-Fisher Scientific) with an injection 
into HESI II in the positive or negative mode.
General procedure for the synthesis of the N-(substituted-phenyl)-1-hydroxynaphthalene-
2-carboxamides. 1-Hydroxynaphthalene-2-carboxylic acid (2.66 mmol) and the corresponding substituted 
aniline (2.66 mmol) were suspended in 25 mL of dry chlorobenzene with phosphorous trichloride (1.33 mmol). 
The reacting mixture was heated in a microwave reactor at the maximal allowed power of 500 W and 130 °C 
using the infrared flask-surface control of the temperature for 15 min. The solvent was evaporated under reduced 
pressure. After evaporation to dryness, the product was washed with 2 M HCl and H2O. The crude product was 
purified by recrystallization from EtOAc or a mixture of EtOH/H2O.
Compounds 1, 2a–c, 3a–c, 4a–c, 5a–c, 5d–l, 5n, 5q, 5t, 6d-h, 6a–c, 7a–c, 8a–c were described recently by 
Gonec et al.88.
N-(2,5-dimethoxyphenyl)−1-hydroxynaphthalene-2-carboxamide (2d). Yield 75%; Mp. 116–119 °C; HPLC 
purity 97.60%; IR (cm−1): 3433, 1634, 1604, 1595, 1538, 1489, 1453, 1413, 1387, 1325, 1276, 1248, 1208, 1200, 
1172, 1150, 1125, 1045, 1021, 951, 866, 835, 806, 792, 762, 723, 711; 1H-NMR (DMSO-d6), δ: 13.66 (s, 1 H), 10.34 
(s, 1 H), 8.33 (dd, 1 H, J = 7.7, J = 1.3 Hz), 8.07 (d, 1 H, J = 8.6 Hz), 7.91 (d, 1 H, J = 8.1 Hz), 7.67 (ddd, 1 H, J = 8.2, 
J = 6.9, J = 1.3 Hz), 7.59 (ddd, 1 H, J = 8.3, J = 7.0, J = 1.2 Hz), 7.53 (d, 1 H, J = 8.8 Hz), 7.43 (d, 1 H, J = 2.9 Hz), 7.06 
(d, 1 H, J = 8.8 Hz), 6.81 (dd, 1 H, J = 8.8, J = 2.9 Hz), 3.82 (s, 3 H), 3.74 (s, 3 H); 13C-NMR (DMSO-d6), δ: 168.20, 
158.43, 152.92, 146.22, 135.97, 128.90, 127.58, 126.54, 125.90, 124.84, 123.62, 123.09, 118.42, 112.35, 111.51, 
110.69, 108.95, 56.24, 55.48; HR-MS: [M-H]+ calculated 322.10739 m/z, found 322.10892 m/z.
N-(3,5-dimethoxyphenyl)−1-hydroxynaphthalene-2-carboxamide (2e). Yield 83%; Mp. 118–121 °C; HPLC 
purity 96.95%; IR (cm−1): 3266, 2999, 2936, 2833, 2540, 1614, 1595, 1549, 1514, 1470, 1453, 1423, 1332, 1296, 
1257, 1227, 1194, 1154, 1064, 985, 846, 813, 799, 711; 1H-NMR (DMSO-d6), δ: 13.93 (s, 1 H), 10.35 (s, 1 H), 8.31 
(d, 1 H, J = 8.2 Hz), 8.11 (d, 1 H, J = 9.2 Hz), 7.91 (d, 1 H, J = 8.2 Hz), 7.67 (ddd, 1 H, J = 8.0, J = 6.8, J = 1.3 Hz), 7.58 
(ddd, 1 H, J = 8.3, J = 7.0, J = 1.2 Hz), 7.47 (d, 1 H, J = 8.9 Hz), 7.05 (d, 2 H, J = 2.3 Hz), 6.36 (t, 1 H, J = 2.3 Hz), 3.77 
(s, 6 H); 13C-NMR (DMSO-d6), δ: 169.49, 160.37, 159.91, 139.34, 135.99, 129.14, 127.47, 125.93, 124.65, 123.07, 
123.01, 117.79, 107.60, 100.13, 96.69, 55.22; HR-MS: [M-H]+ calculated 322.10738 m/z, found 322.10788 m/z.
Other experimental data for the compounds that were synthesized in this study can be found in the supple-
mentary information.
Cell Culture. The human colon cancer cell line HCT116 wild type was obtained from ATCC and the 
normal human fibroblast cell lines NHDF were obtained from PromoCell. The human colon cancer cell line 
HCT116 with a p53 deletion (p53−/−) was kindly provided by Prof. M. Rusin from the Maria Sklodowska-Curie 
Memorial Cancer Centre and Institute of Oncology in Gliwice, Poland89. The cells were grown as monolayer 
cultures in Dulbecco’s modified Eagle’s medium with the antibiotic gentamicin (200 μL/100 mL medium) in 
75 cm2 flasks (Nunc). The DMEM for the HCT116 were supplemented with 12% heat-inactivated fetal bovine 
serum (Sigma-Aldrich, St. Louis, MO, USA) and for NHDF with 15% non-inactivated fetal bovine serum (Sigma 
Aldrich, St. Louis, MO, USA). The cells were cultured under standard conditions at 37 °C in a humidified atmos-
phere at 5% CO2.
Cytotoxicity studies. The cells were seeded in 96-well plates (Nunc) at a density of 5,000 cells/well 
(HCT116) and 4,000 cells/well (NHDF) and incubated at 37 °C for 24 h. The assay was performed following a 
72 h incubation with varying concentrations of the compounds that were being tested. Then, 20 µL of CellTiter 
96® AQueous One Solution-MTS (Promega) was added to each well (with 100 µL DMEM without phenol red) 
and incubated for 1 h at 37 °C. The optical densities of the samples were analyzed at 490 nm using a Synergy 4 
multi-plate reader (BioTek, Winooski, VT, USA). The results are expressed as the percentage of the control and 
were calculated as the inhibitory concentration (IC50) values (using a GraphPad Prism 7). The IC50 parameter 
was defined as the compound concentration that was necessary to reduce the proliferation of cells to 50% of the 
untreated control. Each individual compound was tested in triplicate in a single experiment with each experiment 
being repeated three or four times.
Apoptosis assay. The dual acridine orange/ethidium bromide (AO/EB) staining method was used for the 
morphological analysis of apoptosis. The cells were seeded on coverslips at a density of 8·105 cells/slide and incu-
bated at 37 °C for 48 h. Then, the medium was removed and solutions of 5 s, 5 u, 7 f and DOX at the IC50 concen-
tration were added. After 24 h, the cells were washed with PBS, and then the cells were incubated in a staining 
solution (100 μg/mL AO and 100 μg/mL EB in PBS) (Sigma-Aldrich, St. Louis, MO, USA) for 3–4 min. After 
staining, the coverslips were washed with PBS and fixed with 3.7% paraformaldehyde for 15 min. Observations 
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and photography were performed with a Nikon Eclipse Ni-U fluorescent microscope equipped with the sets of 
filters for AO and EB (excitation filter 450–490, barrier filter BA520).
Immunoblotting. The HCT116 cells were seeded in 3-cm Petri dishes (Nunc) at a density of 0.5·106 cells/
well and incubated overnight. The next day, solutions of anilides (ten-fold IC50 concentration) and DOX (2.5 μM) 
were added and the cells were incubated for 12 or 24 h. The cells were harvested by trypsinization and washed 
with cold PBS. Next, the cells were centrifuged and suspended in an RIPA buffer (Thermo-Fisher Scientific) 
containing Halt Protease Inhibitor Cocktail (Thermo-Fisher Scientific), Halt Phosphatase Inhibitor Cocktail 
(Thermo-Fisher Scientific) along with 0.5 M EDTA and lysed for 20 min on ice. Then, the lysates were sonicated, 
centrifuged at 10,000 rpm for 10 min at 4 °C and the supernatants were collected for further analysis. The protein 
concentration was determined using a Micro BCA™ Protein Assay Kit (Thermo-Fisher Scientific, Waltham, MA, 
USA c) according to the manufacturer’s instructions. Equal amounts of the proteins (20 μg) were electrophoresed 
on SDS-Page gels and transferred onto nitrocellulose membranes. The membranes were blocked in 5% non-fat 
milk prepared in PBS containing 0.1% Tween-20 (TPBS) for 1 h. After blocking, the membranes were incubated 
with specific primary antibodies: p21Waf1/Cip1, p53, cytochrome c, caspase-8, caspase-9, AIF, PARP, GAPDH and 
β-Actin overnight at 4 °C, and then washed and incubated with horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies for 1 h at room temperature. All of the antibodies were purchased from CellSignaling (Danvers, 
MA, USA) and were diluted 1:1000 in 5% milk in TPBS. Finally, the membranes were washed and incubated with 
a SuperSignal™ West Pico Chemiluminescent Substrate (Thermo-Fisher Scientific). The chemiluminescence sig-
nals were captured using a ChemiDoc™ XRS+ System (Bio-Rad Laboratories, Hercules, CA, USA). The exper-
iments were performed at least three times. Densitometric analysis was performed using ImageJ 1.41 software 
(Wayne Rasband, National Institutes of Health, USA).
Intercalation. For the DNA binding studies, Calf-thymus DNA (CT-DNA) was purchased from Sigma- 
Aldrich. The lyophilized CT-DNA was dissolved in 10 mM Tris-HCl, pH 7.9, mixed gently and left overnight at 
4 °C. The purity of the CT-DNA solution was determined by measuring the ratio of UV absorbance at 260 and 
280 nm. A ratio of more than 1.8 indicated that the DNA was sufficiently free of proteins. Then, the concentration 
of CT-DNA was determined from the absorbance at 260 nm using an extinction coefficient of 6600 M−1cm−1. 
The tested compounds including DOX and CP-31398 were dissolved to a concentration of 8.35 mM in DMSO, 
which was then used as the stock solution for preparing the various concentrations (25, 12.5, 6 and 3 µM) in 1 mL 
in 10 mM of Tris-HCl (pH 7.9). Afterwards, 18 µM CT-DNA was added to the prepared solutions, which were 
incubated for 1.5 h at 37 °C with occasional vortexing. The absorption spectra were measured using a Hitachi 
U-2900 spectrophotometer in the range of 200–500 nm. All absorption spectra were imported into OriginPro 
8.0 and compared.
CoMFA and CoMSA approaches. Comparative molecular field analysis (CoMFA) is a widely used pro-
cedure for simulating the influence of the molecular shape when modeling steric (Lennard-Jones) and elec-
trostatic (Coulomb) fields as being important intermolecular interactions that are involved in non-covalent 
ligand-receptor binding90. Generally, the CoMFA approach is based on the assumption that a comparative anal-
ysis of the 3D patterns that are produced within the cubic mesh of points that encompasses aligned molecules 
using suitable probes can account for the differences in the binding affinities or the biological activity profiles 
for a congeneric series of compounds. In fact, the modeling efficiency of the electronic and steric potentials in 
the molecular environment is strictly dependent on the selection of a suitable atomic probe (usually z positively 
charged sp3 carbon atom) and the superimposition that is applied following the putative pharmacophore hypoth-
esis. As a result, the distribution of the potential values on the mesh points relies on the molecular coordinates, 
which are valid factors that control the value of the atomic partial charges. The resulting potential energies at each 
lattice point can be illustrated graphically as a three-dimensional color contour pattern that indicates the spatial 
areas, where a steric hindrance and/or charged substituents enhances or diminishes the binding affinity91.
A self-organizing neural network (SOM) data processing was performed as described earlier92.
PCA and PLS procedures. The partial least squares (PLS) method produces a relationship between variable 
Y and an ensemble of descriptors X, which are expressed in the form of the equation:
= +bXY e (1)
where b = a vector of the regression coefficients and e = a vector of the errors.
The generated data are centered and processed by the PLS analysis by constructing models the complexity of 
which is estimated using the leave-one-out cross-validation procedure (CV). In the leave-one-out CV, one repeats 
the calibration m times, each time treating the i-th left-out object as the prediction object93.
A cross-validated leave-one-out q2CV value to estimate the performance of a model is computed using the 
following formula:
= − ∑
−
∑ −
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obs mean obs
1
( )
( ( )) (2)CV
i
m
i i
i
m
i i
2
2
2
where obs is the assayed value; pred - predicted value; mean - mean value of obs and i refers to the object index.
The quality of external predictions is measured by the standard deviation of error of prediction (SDEP) and 
q2test defined as:
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The uninformative variable elimination (UVE-PLS) as well as its modifications, namely, modified UVE 
(m-UVE) and iterative variable elimination (IVE-PLS) have been applied in both QSAR and QSPR schemes, 
respectively94. The original UVE algorithm, which was developed by Centner et al., analyzes the reliability of 
the mean(b)/s(b) ratio, where s(b) is the standard deviation of regression coefficient b, which is calculated using 
the PLS method95. Then, only variables with relatively high stability values are included in the final PLS model. 
In the current calculations, the iterative IVE-PLS procedure was used as a modification of the single-step UVE 
algorithm in order to identify the variables to be eliminated. Basically, the entire algorithm is composed of the 
following stages:
Step 1. Standard PLS analysis with LOO-CV to evaluate the performance of the PLS model (q2CV).
Step 2. Elimination of the matrix column with the lowest abs(mean(b)/std(b)) value.
Step 3. Standard PLS analysis of the new matrix without the column that was eliminated in step 2.
Step 4. Iterative repetition of the steps 1 to 3 to maximize the LOO q2CV parameter.
Model builder. All of the pharmacological data were specified by the same laboratory in order to eradicate 
any potential data noise introduced by pooling the data sets from various sources. The in vitro efficiency of the 
anticancer hydroxynaphthanilides is presented in Table 1. The constitution of the molecular models was gen-
erated using the CACTVS/csed molecular editor. The spatial geometry of the molecules was formed with the 
CORINA 3D. The (inter)change file format converter OpenBabel was used in file preparation.
Molecular modeling. The modeling were performed using the Sybyl-X 2.0/Certara software package running 
on an HP workstation with a Debian 6.0 operating system. The initial geometry for all compounds was generated 
using the MAXMIN2 module in which the standard Tripos force field (POWELL conjugate gradient algorithm) with 
0.01 kcal/mol energy gradient convergence criterion and a distant dependent dielectric constant were applied. The 
Gasteiger-Hückel procedure, which was implemented in Sybyl to calculate the electrostatic potential, was initially used 
to calculate the partial atomic charges. The one 14-ordered atom trial alignment on molecule 1 was selected to cover 
the entire bonding topology in the maximal common structure (1-hydroxynaphthalene and peptide-like motif) using 
the atom FIT method as is presented in Table 1. The sp3 hybridized carbon probe atom with a charge of +1 and 0 and 
hydrogen as the probe atom with a charge of +1 were used to calculate the electrostatic and steric fields, respectively. 
The CoMFA grid spacing was 2.0 Å for all of the Cartesian dimensions within the defined region of the 3D lattice, which 
extended beyond the van der Waals envelopes of all of the molecules by at least 4.0 Å. The non-covalent interaction 
fields were specified at each intersection on a regularly spaced grid of points.
For each molecule, the energies with a total of 864 grid points were calculated with 2 Å spacing in a 12 × 9 × 8 
lattice. All of the columns with an energy variance of less than 2.0 kcal/mol were discarded by setting the sigma 
parameter to 2.0 kcal/mol in order to reduce any data noise. Both the steric/electrostatic energies with a value 
greater than 30.0 kcal/mol were truncated to a tentative value of 30.0 (default cut-off). The SAMPLS method 
using the standard internal and external validation techniques was used to determine the statistical index of the 
predictive power of a model describing the variations in the CoMFA interaction fields (independent variables) 
and changes in activity (dependent variable).
The SONNIA software was used in the CoMSA analysis to simulate 20 × 20 or 30 × 30 SOMs with a winning 
distance (md) that varied within the range of 0.2 to 2.0. The Cartesian coordinates of the molecular surfaces for 
the superimposed molecules were preceded by the SOM network to form a two-dimensional map of the electro-
static potential – the most active analog (8c) was also used to form the template molecule.
The output maps were subsequently transformed into a 400- or 900-element vector, which was processed using 
the PLS method implemented in the MATLAB programming environment corresponding to the CoMFA analysis.
Data Availability
The datasets that were generated and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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